Search
Aug 9, 2024
Scholar Rock's CEO on a big phase 3 readout coming later this year in SMA, myostatin inhibition for obesity, and more
Jay Backstrom describes the company's approach of targeting the latent form of growth factors, the importance of the upcoming SAPPHIRE...